Published in Hum Vaccin Immunother on October 29, 2012
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev (2013) 2.46
Heat-shock proteins as dendritic cell-targeting vaccines--getting warmer. Immunology (2013) 0.98
Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab. Oncotarget (2016) 0.75
Inflammation and cancer. Nature (2002) 53.78
Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotide sequence of human hsp70. Proc Natl Acad Sci U S A (1985) 6.45
CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity (2001) 4.16
Targeting the ubiquitin system in cancer therapy. Nature (2009) 3.27
Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol (2001) 3.12
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2.79
Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med (1997) 2.59
Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol (2004) 2.59
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun (2010) 1.64
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol (2007) 1.60
Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med (1998) 1.57
Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J Immunol (2002) 1.54
The heat-shock protein receptors: some answers and more questions. Tissue Antigens (2004) 1.42
Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol (1996) 1.38
Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming. Eur J Immunol (1992) 1.36
HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol (2003) 1.23
Heat shock proteins and toll-like receptors. Handb Exp Pharmacol (2008) 1.23
In vivo activities of GroEL minichaperones. Proc Natl Acad Sci U S A (1998) 1.16
Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proc Natl Acad Sci U S A (2008) 1.14
Structure and function: heat shock proteins and adaptive immunity. J Immunol (2007) 1.12
Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev Vaccines (2011) 1.11
Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83. Mol Immunol (1999) 1.07
Heat shock protein 70 (HSP70) induces cytotoxicity of T-helper cells. Blood (2008) 1.05
Molecular chaperones in mammary cancer growth and breast tumor therapy. J Cell Biochem (2012) 1.05
Facets of heat shock protein 70 show immunotherapeutic potential. Immunology (2003) 1.04
Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70. Int Immunol (2001) 1.02
Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines (2008) 1.00
Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother (2005) 0.99
Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol (2005) 0.96
Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine (2008) 0.95
Heat shock protein as molecular targets for breast cancer therapeutics. J Breast Cancer (2011) 0.93
Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells and adjuvanticity. Biochem Soc Trans (2004) 0.93
T cells and autoantibodies to human HSP70 in type 1 diabetes in children. J Autoimmun (2003) 0.92
Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin (2009) 0.90
Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response. Cell Stress Chaperones (2005) 0.89
Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Exp Parasitol (2010) 0.89
The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells. Int Immunol (2006) 0.88
Cross-reactive mycobacterial and self hsp60 epitope recognition in I-A(g7) expressing NOD, NOD-asp and Biozzi AB/H mice. J Autoimmun (2002) 0.88
A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine (2008) 0.88
A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Vaccine (2006) 0.87
DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol (2004) 0.87
Recent advances in heat shock protein-based cancer vaccines. Hepatobiliary Pancreat Dis Int (2006) 0.87
Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice. World J Gastroenterol (2005) 0.85
Heterologous expression of FMDV immunodominant epitopes and HSP70 in P. pastoris and the subsequent immune response in mice. Vet Microbiol (2007) 0.84
Heat shock proteins as immunological carriers and vaccines. EXS (1996) 0.84
Heat shock proteins HSP70 and GP96: structural insights. Cancer Immunol Immunother (2005) 0.84
From minichaperone to GroEL 1: information on GroEL-polypeptide interactions from crystal packing of minichaperones. J Mol Biol (2000) 0.84
A novel vaccine strategy to induce mycobacterial antigen-specific Th1 responses by utilizing the C-terminal domain of heat shock protein 70. FEMS Immunol Med Microbiol (2011) 0.84
The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. J Neuroimmunol (1996) 0.83
The immunization of A2/K(b) transgenic mice with the KMP11-HSP70 fusion protein induces CTL response against human cells expressing the T. cruzi KMP11 antigen: identification of A2-restricted epitopes. Mol Immunol (2001) 0.83
Hsp-based tumor vaccines: state-of-the-art and future directions. Curr Opin Mol Ther (2007) 0.83
Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene. Vaccine (2005) 0.82
GP96 C-terminal improves Her2/neu DNA vaccine. J Gene Med (2010) 0.82
N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine. Cell Stress Chaperones (2010) 0.82
Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model. Cell Stress Chaperones (2010) 0.82
Role of antiheat shock protein 60 autoantibodies in atherosclerosis. Lupus (2005) 0.82
DNA immunization as an efficient strategy for vaccination. Avicenna J Med Biotechnol (2009) 0.81
Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients. Indian J Med Res (2009) 0.80
Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent. Cell Stress Chaperones (2010) 0.80
In vitro reconstitution of heat shock protein-peptide complexes for generating peptide-specific vaccines against cancers and infectious diseases. Methods (2004) 0.80
Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70. Biologicals (2011) 0.79
Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections. Mol Immunol (2012) 0.79
Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein. Mol Biol Rep (2009) 0.78
The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model. Scand J Immunol (2012) 0.78
Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice. Vaccine (2011) 0.78
Fusion expression of major antigenic segment of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70. Vet Immunol Immunopathol (2006) 0.78
Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model. Cell Stress Chaperones (2011) 0.77
A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice. Int Immunopharmacol (2012) 0.77
Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol (2008) 1.46
Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res (2006) 1.39
Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol (2010) 1.25
Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer (2011) 1.16
In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response. PLoS Negl Trop Dis (2011) 1.05
In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications. Theor Biol Med Model (2009) 1.03
Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. Vaccine (2008) 1.00
Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines (2008) 1.00
Leishmaniasis: Middle East and North Africa research and development priorities. PLoS Negl Trop Dis (2011) 0.99
Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine (2008) 0.95
Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine (2009) 0.93
CD8(+) T cells in leishmania infections: friends or foes? Front Immunol (2012) 0.92
Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice. Plant Sci (2011) 0.92
Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release (2011) 0.91
The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women. Diagn Microbiol Infect Dis (2007) 0.90
Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin (2009) 0.90
Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl Trop Dis (2013) 0.89
Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Exp Parasitol (2010) 0.89
Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine (2004) 0.89
Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice. Virus Genes (2009) 0.87
Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7. Vaccine (2010) 0.87
Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett (2009) 0.87
Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J Pharm Pharm Sci (2010) 0.85
Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model. Immunotherapy (2012) 0.85
Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population. Vet Parasitol (2004) 0.85
Biological delivery approaches for gene therapy: strategies to potentiate efficacy and enhance specificity. Mol Immunol (2013) 0.83
Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. J Biotechnol (2006) 0.83
Chemokine-based immunotherapy: delivery systems and combination therapies. Immunotherapy (2012) 0.81
Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae. Parasitol Res (2011) 0.81
Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity. Exp Parasitol (2010) 0.81
Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients. Indian J Med Res (2009) 0.80
A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers. Drug Deliv (2013) 0.80
The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Deliv (2009) 0.79
Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections. Mol Immunol (2012) 0.79
Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J Control Release (2010) 0.77
Murine cytokine patterns following rubella vaccination. Iran J Allergy Asthma Immunol (2003) 0.77
Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun (2003) 0.77
C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice. PLoS Negl Trop Dis (2011) 0.76
Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate. PLoS Negl Trop Dis (2013) 0.76
Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model. Exp Parasitol (2011) 0.76
Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. Expert Rev Vaccines (2012) 0.76
Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model. Immunol Lett (2012) 0.75
PUF Proteins: Cellular Functions and Potential Applications. Curr Protein Pept Sci (2017) 0.75
Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96. Arch Virol (2014) 0.75
Innate immune system: specific or non-specific? Med Hypotheses (2007) 0.75